Buy in Glooooooom Sell in Boooooooooom.The cost overrun does not say that the resources dont exit. The cost overrun is not significant to dent profits
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%